Chemomab Reports New Peer-Reviewed Publication Reinforcing The Clinical Association Of Its CCL24 Target with Disease Severity and Mortality In Systemic Sclerosis
Portfolio Pulse from Benzinga Newsdesk
Chemomab announced a new peer-reviewed publication that supports the clinical association of its CCL24 target with disease severity and mortality in Systemic Sclerosis (SSc). A longitudinal study of over 200 real-world patients further validates CCL24 as a novel target for SSc, indicating its association with disease severity across fibrotic and vascular manifestations of the condition.
April 18, 2024 | 11:11 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Chemomab's new publication validates CCL24 as a target for Systemic Sclerosis, potentially impacting the company's research direction and future revenue streams.
The publication of peer-reviewed research supporting Chemomab's CCL24 target for Systemic Sclerosis treatment highlights the potential for this target to play a significant role in developing new treatments. This could positively impact Chemomab's stock as it reinforces the company's research direction and potential for future revenue streams from novel treatments.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90